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INTRODUCTION
Hansens  disease  is  a  granulomatous  infectious  disease  caused  by 
Mycobacterium leprae.  It affects mainly peripheral nerves but it can also 
affect skin, muscles, eye, bone, testes and internal organs.                        
        Although  much  improved  in  last  25  years,  knowledge  of  the 
pathogenesis, course, treatment and prevention of the disease continues to 
evolve. The skin lesions and deformities were historically responsible for 
stigma attached to the disease. The introduction of MDT in early 1980 had 
begun to have an impact on the transmission of disease and severity of its 
attending complications.
    Eye  involvement  in  leprosy  is  quite  common.  Its  complications, 
particularly  sight  threatening  complications,  if  neglected  will  lead  to 
blindness.
     Good  vision  is  required  not  only  for  performance  of  routine 
activities  but  also  for  the  care  of  anaesthetic  hands  and  feet.  Loss  of 
eyesight in a person who already have anaesthesia in hands and feet is a 
disaster.
       Ocular lesions range from chronic irritation of eyes to blindness. The 
incidence of eye involvement in leprosy is stated to be anywhere from 15 
% (tuberculoid) to 100% in long standing lepromatous leprosy.
       Ocular  involvement  had  been  seen  even  in  patient  who  have 
completed  the  MDT.  Every  year,  approximately  5.6% of  patients  with 
multibacillary leprosy who completed MDT can be expected to develop 
new ocular  complications of leprosy which often (3.9%) are potentially 
vision  threatening.   Similarly  complications  can  occur  during  MDT 
therapy and during relapse of the disease.
        Ocular morbidity like orbicularis weakness and lagophthalmos are 
found to be more in patients with reversal reaction. Elderly, deformed, skin 
smear positive lepromatous patients are associated with increased ocular 
morbidity  and form a  group that  require  acceptable  and accessible  eye 
care.
        This  study aims at  determining the incidence of  various ocular 
manifestations of leprosy and its management.                                         
                                                                        
                                                    
                                   MYCOBACTERIOLOGY
  MORPHOLOGY  : 
Mycobacterium leprae belongs to Actinomycetales and family 
Mycobacteriaceae  which are rod shaped aerobic and non sporing bacteria. 
The  organism  does  not  stain  readily  but  once  stained  they  resist 
decolourisation by acid or alcohol and hence called acid-fast bacillus. It 
occurs singly in parallel bundles or in globular masses and often found 
within  endothelial  cells  of  blood  vessels,  in  mononuclear  cells  or  in 
schwann  cells  and  is  the  only  mycobacterium  that  infects  peripheral 
nerves. Its long generation time (12-13 days) is responsible for chronicity. 
The bacteria involves cooler tissues of the body such as skin, superficial 
nerves, nose, pharynx, eyes and testicles.   This organism was described 
by Armauer Hansen in 1873  .
CULTIVATION  :
                It has not been cultivated on non-living bacteriological media. 
(Dasypus  novemcintus)  the  nine  branded  armadillo  is  susceptible  to 
mycobacterium leprae  possibly  because  it  has  a  low body temperature. 
About 40% of Armadillos inoculated with Mycobacterium leprae develop 
florid lepromatous leprosy, both clinically and histopathologically after a 
year or more.
       However real break through was discovered by Shepard (1960) that 
leprae bacilli could multiply in footpad of mice kept at low temperature20 
degree Celsius. Following intradermal inoculation into footpad of mice, a 
granuloma develops at the site in 1-6 months. 
        This  technique  had  been  utilized  in  diagnosis  of  the  disease,  
evaluation of potency of antileprosy drugs and detection of viability of the 
bacilli during treatment.
        One of the best known reports of cultivation is from Indian cancer 
research center  Bombay where AFB was isolated from leprosy patients 
employing fetal ganglion cell culture.
  Resistance :
         Lepra  bacilli   is  found  to  remain  viable  in  a  warm  humid 
environment for  9-16 days and in moist  soil  for  46 days. They survive 
exposure to direct sunlight for 2 hours and UV rays for 30 minutes.
HISTORICAL BACKGROUND
The  history  of  mans  relationship  with  leprosy  has  always 
invoked a great deal of speculation.
    Word leper is derived from Greek language.  The word  leper 
means scaly.  The disease is thought to have had its origin in Asia. The 
earliest records of leprosy like disease is from India and  China as early as 
600 B.C. In India leprosy has been known since ancient times as kustha 
roga (in Sanskrit). Chaulmoogra oil was used as  treatment for kustha roga.
     The earliest evidence of leprosy is the mummies of second century B.C. 
The disease probably was carried from India to Europe in fourth century 
B.C  by  the  returning  Greek  soldiers.  From Greece,  the  disease  spread 
slowly  throughout  Europe  where  the  maximum  period  of  activity  was 
between tenth and fifteenth centuries. Subsequently the disease underwent 
a steady and significant decline to 1/1,00,000 by the year 1900, due to the 
strict isolation of patients and improvement in the quality of life of the 
people .
      For a long time the disease was thought to be a curse or punishment 
from God. It was only after several centuries that the causative organism-
Mycobacterium leprae was discovered by Armauer Hansen of Norway in 
1873, yet there was no effective remedy for the disease . For long time the 
only way to handle leprosy patients was to isolate them for life in special 
situation.   With  the  introduction  of  sulfone  drugs  in  the  treatment  of 
leprosy in 1943 marked the beginning of new era- the era of case finding 
and domiciliary treatment
     With this and the magnitude of the disease in our country in mind, the 
government of India launched the National Leprosy Control Programme 
(NLCP) in 1955.
        The development of experimental animal models occurred in 6o and 
70”s.  In  1960 – Shepard discovered M.leprae could multiply to  certain 
extent when injected into footpads of mice .In 1971 Krichheimer in USA 
paved the way for vast experimental work in leprosy research. He reported 
that  armadillos  developed  disseminated   leprosy  when  injected 
experimentally with M.leprae.
     Thus  NLCP in  India  was  redesigned  as  NLEP (National  Leprosy 
Eradication Programme) in 1983, with the goal of arresting the disease, by 
the start of twenty first century.
EPIDEMIOLOGY
            The evolution of leprosy as a disease has been slow that its  
epidemiological  pattern,  probably  extending  over  several  centuries  was 
poorly documented than acute disease such as plaque   worldwide.
           The  disease  and its  various  clinical  forms  is  not  uniformly 
distributed.  The  disease  had  died  out  completely  in  Northern  Europe, 
Hawai,  Japan,  Venezuela,  United  States  of  America.  This  is  due  to 
economic development in these countries leading to change in risk factors. 
It is still endemic at a low level in part southern and Eastern Europe, South 
east Asia, Africa and Western pacific where poverty and low standard of 
living  still  persist.  Estimated  number  of  cases  is  about  10-12  million. 
Accurate assessment is not possible because the endemic population are 
those of developing countries where reporting systems are poor.
Leprosy :
        Leprosy is a major health problem in India. According to WHO 
expert  committee,  a  public  health  problem  is  said  to  exist  when  the 
prevalence of leprosy is around 1/4000 population.
      In 1981 number of cases is about 4 million. Prevalence being 5.7 /1000 
population.  Almost all states in India have a leprosy problem, there is a 
great degree of variability. The disease is more prevalent in southern and 
eastern regions than in northern region of the country. States maximally 
affected  are  Tamilnadu,  Pondicherry,  Bihar  and Orissa  with  prevalence 
being >5/1000 population.
         Ocular complications occur in 10%-90% of patients and probably 
occur more frequently during leprosy than in any other systemic infectious 
disease.  Approximately  5%  -  10%  of  patients  with  ocular  leprosy  are 
blinded  by  the  disease  and  a  million  or  more  leprosy  patients  have 
substantial vision loss from leprosy.
                             CLASSIFICATION
Leprosy  has  been  classified  based  on  clinical,  bacteriological, 




 Tuberculoid type 
 Borderline type
 Lepromatous type
 Pure neuritic type
Matrid classification :
 Indeterminate
 Tuberculoid- flat : raised
 Borderline 
 Lepromatous 
Ridley and jopling classification :
    According to their position on immunological scale it is divided into
 Tuberculoid (TT)
 Borderline tuberculoid (BT)
 Borderline  (BB)
 Borderline lepromatous(BL)
 Lepromatous type (LL)
The  Indian  and  matrid  classification  systems  are  the  most 
widely used classifications in leprosy field programmes, whereas Ridely 
and Jopling classification can be used only when full research facilities are 
available.
CLINICAL FEATURES OF   LEPROSY
Cardinal signs of leprosy  :
                                Mycobacterium leprae (causitive  organism)
                                                                ↓
                                            Affinity  to nerves
                                                                ↓
                                                  Inflammation
                                                                ↓
                                     Enlargement and tenderness  of nerves
                                                                ↓
Further inflammation  → loss of nerve tissues →  loss of function 
                                                                 ↓
        Sensory fibers are affected first leading to loss of sensation in the skin 
lesion  (or)  in the  area supplied by the nerve.
Atleast any one of the above three signs must be there to diagnose leprosy.
Leprosy by WHO case definition :   
 A person having one / more of the following features  
1)   Hypopigmented / reddish skin lesions with definite loss of sensation
2)   Involvement of peripheral nerves as demonstrated by definite
       thickening with loss of sensation.
3)   Skin smear positive for AFB
Systemic features  :
          Mycobacterium leprae regardless of the route of entry into human 
body, only a proportion of persons infected develop signs of the disease 
after the incubation period of 3-5 years. Majority will develop sub-clinical 
infection. The initial sites of infection are the peripheral nerves with target 
organ being schwann cell. Thus the most common first symptom is a small 
but  persistent  area  of  impaired  sensation/numbness.  In  others,  first 
noticeable feature may be macules which are usually hypopigmented and 
erythematous .
Tuberculoid leprosy :
 Skin lesion :
        It is documented by few (usually 3) solitary lesions affecting skin and 
peripheral  nerves.   The margins  are usually  well  defined,  with dry and 
rough surface.  The lesions are firm in consistency.  There is no central 
healing.  It is usually associated with loss of hair, loss of sweating and 
anaesthesia.  Lesions are usually asymmetrical.
Nerve lesions :             Nerve involvement is common in this type of 
leprosy.    Nerves  close to the skin lesion are usually  affected.   Nerve 
abscess are more common. Systemic involvement is less common.
Lepromatous leprosy :
Skin lesions :
           Lesions are ill defined, multiple, with smooth surface and soft in 
consistency.  Lesions are usually symmetrical.
Nerve involvement :
        Nerve involvement occurs  in late stage.  Multiple nerves are affected.
Systemic involvement :
       Systemic involvement is more common and severe in lepromatous 
leprosy.   Eye , nose , larynx and  testes are involved .
Ocular features of leprosy :
      Blindness is common and disastrous complication in leprosy.  In 1873 
Hansen  stated  “There  is  no  disease  which  so  frequently  gives  rise  to 
disorders of the eye as leprosy does”.  The ocular adenexa and anterior 
segment of the eye offer an ideal site for the proliferation of M.leprae.  The 
cooler  temperatures, the presence of a rich  neurovascular network and the 
possibility  of  ocular   immunologic  compartmentalization  may  all  be 
incriminated as contributing to ocular complication during leprosy.  Ocular 
complications occur in 1/3 of  leprosy patients.
        For simplicity ocular lesions are classified into two groups. The first  
group include potentially sight threatening lesions (PST) which includes 
lagophthalmos  and  its  sequelae,  chronic  iridocyclitis  and  its  sequelae. 
Lesions such as loss of eyebrows and eyelashes have no visual significance 
but contribute to the stigma which these patients endure. 
Process by which eye can be damaged  :
1) Exposure and anaesthesia :
         Involvement of occipital, temporal and zygomatic branches of the 
facial  nerve  produce  selective  paralysis  of  orbicularis  oculi  muscle. 
This is usually seen to occur during type I reactions and in untreated 
lepromatous leprosy on later stages.
         Bacillary infiltration of the superficial muscles of the face also 
cause weakness in lepromatous leprosy. Lagophthalmos develops and 
blinking  is  incomplete.   Cornea  and  conjunctiva  become  prone  to 
drying and to minor trauma.   In tuberculoid lesions of face,  entropion 
and trichiasis develops due to scarring of the tarsal plate. 
2) Bacillary invasion :
          Bacillary invasion of the eye occurs through both the blood 
stream and via the corneal nerves, thus mainly involving cornea and 
ciliary body.
3) Hypersensitivity  :
          Iris and ciliary body that have been involved by the leprosy 
bacilli are prone to severe damage during type 2 lepra reaction. These 
may be the sites of deposition of circulating immune complexes even 
when there is no bacilli. 
Ocular manifestations of leprosy :
  Eyebrows                - Madarosis
  Lids                       - Lagophthalmos
                                - Entropion
                                - Ectropion
                                 - Trichiasis
                                     - Lid nodules
  Meibomian glands      - Tear film abnormalities
  Lacrimal glands      - Acute and Chronic                      
                                 Dacryoadenitis
  Sclera                     - Scleritis
- Episclerits
      Cornea                     - Hypesthesia
                                       -           Avascular keratitis
                                       -           Corneal leproma
                                       -           Interstitial keratitis
   Iris and ciliary body    - Acute and Chronic
                                        - Iridocyclitis
                                        - Iris leproma   
 Lens                          - Complicated cataract
 Raised IOP               - Secondary open angle Glaucoma 
 Posterior segment     - Choroidal and retinal  pearls
                                  - Choroiditis
External adenexal involvement   :
Eyebrows :
               Thinning of eyebrows and subsequent loss is one of the most  
common manifestations of leprosy. This begins temporally and progresses 
nasally  probably because temporal  brow is  relatively cooler.  Brow loss 
may be total and permanent.
Eyelids  :
        Seventh nerve palsy results in lagophthalmos, lower lid ectropion, 
occasionally upper lid entropion and  poor lacrimal drainage. All leprosy 
patients  regardless  of  their  clinical  disease  are  at  at  risk  of  developing 
lagophthalmos.  Paucibacillary  patients  and  those  in  reversal  reaction 
develop  paralytic  lagophthalmos  earlier  and  suddenly.  Multibacilary 
patients  develop  paresis  later  in  the  disease  and  often  also  develop 
anaesthesia  of cornea and conjunctiva due to involvement  of trigeminal 
nerve.
            Fifth  and  seventh  nerve  involvement  leads  to  exposure 
keratitis(neuroparalytic  and  neurotrophic),  dry  eyes,  dermalization  of 
cornea  and  conjunctiva.  Trichiasis,  susceptibility  to  trauma  resulting  in 
corneal scarring and  blindness.
          Eyelid nodules and placoid lesions develop in paucibacillary, 
reversal,  ENL reaction.  There  is  a  positive  correlation  between  type  1 
reaction lesions on the face and subsequently lagophthalmos  which may 
identify  those  patients  who are  at  risk  of  developing corneal  blindness 
from exposure keratitis. Loss of skin elasticity, infiltration of marginal and 
pretarsal fibers of orbicularis oculi muscle by M.leprae and loss of muscle 
tone  contributes  to  dermatochalasis  and  heavy   drooping  upper  lids. 
Further  atrophy at  the  canthal  tendons and tarsal  plates   creates  heavy 
floppy lids  allowing ectropion perhaps entropion and trichiasis.
Meibomian gland :
        Meibomian  gland  infiltration leads to atrophy and inadequate lipid 
production with associated  tear dysfunction. 
Lacrimal gland and lacrimal sac :
           Acute and chronic  dacryoadenitis arising from cellular infiltration 
and inflammation of lacrimal gland  may occur in lepromatous leprosy. In 
tuberculoid lesion, denervation of gland results in keratoconjuntivitis sicca 
Severe  nasal  infiltration and mucosal  scarring lead to  NLD obstruction 
and subsequent dacryocystitis in lepromatous patients.
Cornea :  
          M.leprae  invades cornea through rich network the rich network of 
limbal ciliary nerves during early stage. Hematogenous spread occur later 
by way of blood vessels of corneal pannus. 
         Corneal hypesthesia  may be found in all forms of the disease and 
may lead to inadequate blink reflex which coupled with lagophthalmos, 
ectropion  and  dry  eyes  leads  to  typical  inferior  exposure 
keratoconjunctivitis   .  This  is  an  early  warning  sign  of  inadequate 
protection and increased risk of bacterial corneal infection and may leading 
to blindness.
       Enlarged edematous cornea nerves are found in  lepromatous leprosy. 
The nerve involvement has the appearance of focal swelling resembling 
“bead  of  string “and  consists  of  M.leprae  and  a  surrounding 
granulomatous response within the cranial nerve.
        These nerve swellings are pathognomonic  of leprosy and may be the 
first  sign  of  ocular  and systemic  leprosy.  The  nerve  changes  represent 
granulomatous reactions that resolve spontaneously. Following treatment 
lesions  sometimes  calcify  and  persist.  Later  it  leads  opacification  of 
cornea.
         Avascular keratitis  is characterized by the development of chalky 
white  punctate  subepithelial  opacities  that  are  first  seen  in  superior 
temporal  quadrant  near  the  limbus.  They  are  usually  found  in 
asymptomatic non-inflammed eye.
        Historically the lesion represents miliary lepromas and consists of 
macrophages packed with leprae. The lesion becomes gradually confluent 
and  less  demarcated  causing  surrounding  cornea  hazy.  Later  there  is  a 
destruction of bowmans layer  and superficial vascularisation produces the 
classical lepromatous pannus.
      Corneal lepromas appear as large white or yellowish nodules at the 
limbus.  They  represent  large  granulomata  and  are  relatively  infrequent 
except in Japan and South America. They occasionally encroach upon the 
visual axis.
        Interstitial keratitis begins in superotemporal quadrant and represent 
a more severe form of avascular keratitis that progresses to necrosis and 
later avascular invasion.        
Sclera  :
         Nodular episclerits and scleritis usually consists of focal leproma 
and an inflammatory response. Diffuse episcleritis and scleritis may also 
occur  as  an  immunologically  driven  disease  with  immune  complex 
deposition without direct bacillary invasion. It is typically observed during 
lepra  reactions  and  is  often  associated  with  keratitis  or  iridocyclitis. 
Chronic / recurrent scleritis may lead to scleral necrosis, scleral melting 
and staphyloma.
Iris and ciliary body :
        Uveal tract involvement is primarily seen in lepromatous  leprosy 
and its incidence is directly proportional to disease duration.
Lepromatous iridocyclitis :
    It  may  be  1)  Caused  by  direct  invasion  of  M.leprae  into  ocular 
structures, hematogenous or by the way of ciliary nerves.
2) Neuroparalytic  - as a result of early involvement of iris sympathetic 
nerves.
Evidences for neuroparalytic iritis are :
1) Organismal :
a)   Preferential attachment of lepra bacilli  to nerves in various 
organs, a similar manner of affliction may occur in iris.
b)   Preferential  lodgement  of  organisms in  cooler  parts  of  the 
body (testes, nose ,ear).  As iris temperature is 3.6 degree less 
than  the  body  temperature  (Schwartz  –  1962)  it  can  be 
preferential site. 
2) Clinical    : 
a) Sluggishly reacting pupils with anisocoria without overt signs of 
uveitis goes in favour of neuroparalytic basis.
b)  Corneal  nerve  involvement  is  a  well  known clinical  entity  in 
leprosy. A parallel situation might occur in iris.
3) Pharmacological  :
 a)   Early autonomic denervation hypersensitivity has been described 
by Bauschard and Swift (1972) in which pupils of lepromatous patients 
responded positively to epinephrine in an abnormal way.
      b) Poor response to anticholinergic drugs like atropine as the basic 
fault lies in adrenergic nerve fibres.
4) Histopathological :      
       Lack of organisms in aqueous / iris and functional changes are 
much more marked as compared to organic iris changes.
    A uveal hypersensitivity to M.leprae  has been isolated from normal 
appearing eyes and it has been that iris is a site in which M.leprae might 
survive  long  after  skin  smears  have  become  negative.  Early  subtle 
involvement  includes  diminished  pupillary  reactions,  denervation 
hypersensitivity  to adrenergic  agents and reduced accommodation.
Iris involvement can be divided into 
1) Acute diffuse  plastic iridocyclitis :
          Acute  non-granulomatous  iridocyclitis  is  a  common often 
bilateral accompaniment of type 2 reaction. Its clinical presentation is 
similar to other non- leprous iritis. The course of the disease is often 
fulminant with a sudden painful onset, conjuctival hyperemia, keratic 
precipitates, aqueous cells often with hypopyon formation ,  posterior 
synechiae and secondary glaucoma. Spontaneous hyphaema may also 
occur as a result of fragility of iris vasculature.
2) Chronic iridocyclitis :
           The  more common chronic iridocyclitis is less dramatic but 
potentially  blinding.  It  is  a  low  grade  granulomatous  or   non-
granulomatous  iridocyclitis  common in lepromatous  leprosy but also 
seen in tuberculoid form. It is characterized by a lack of symptoms and 
overt signs. Although slit lamp examination may show aqueous cells 
and  flare  with  keratic  precipitates  scattered  all  over  corneal 
endothelium. Its chronic course leading to iris atrophy and polycoria. 
Iris adhesions progress to seclude and occlude the pupil. Small  non-
reacting pupils caused by the involvement of sympathetic iris nerves, 
exaggerate visual impairment created by developing lens changes and 
corneal opacities.
      The presumed pathogenesis of chronic lepromatous iritis is that 
during primary bacteremia, bacilli lodge in autonomic fibres of iris and 
cause a slow degeneration of nerves which cause a muscular atrophy . 
Due to  atrophy of  muscular  toxins are  released which causes  a  low 
grade  uveitis  with  mild  flare,  KP’s  and  cells  with  eyes  remaining 
essentially white and asymptomatic. 
3)Miliary iris lepromas : 
         There are small glistening white lesions which are  pathgnomonic 
for leprosy. They represent aggregates of tightly packed living and dead 
bacilli  lying  within  mononuclear  cells.  Iris  pearls  usually  develop 
within  a  year  or  two  of  the  commencement  of  iritis  with  little 
accompanying  inflammation or foreign body reaction.
           Iris pearls are situated mainly at the papillary margin around the 
collarette  resembling  a  necklace.  Pearls  may  also  develop in  slowly 
increase in size and may tend to aggregate. They become pedunculated 
and  may  eventually  drop  in  AC  where  they  are  well  tolerated  and 
produce no reaction. 
4)  Nodular iris lepromas :  
          Bacterial invasion of the iris may also give rise to the formation 
of nodular leproma which are yellow globular polymorphic masses that 
occur less commonly than the iris pearls. They occur rarely disrupt the 
architecture.
5)  Iris atrophy :   
            In lepromatous leprosy the so called chronic iritis produces iris 
atrophy  with  small  non-reacting  pupils  which  exaggerate  the  visual 
impairment  created by developing lens changes and corneal opacities. 
The cause of this chronic iritis is believed to be neuroparalytic from 
early involvement of the small nerves of the iris particularly autonomic 
supply.
               Histopathology discloses far more silent chronic iridocyclitis 
in leprosy patients that are diagnosed clinically. AFB can persist in this 
tissue even after completion of MDT. Smooth muscle disruption and 
destruction a cause of miotic  pupil  in leprosy has been conclusively 
demonstrated histopathologically. Iris atrophy continues to develop in 
3% patients with  multibacillary leprosy. Every year after they complete 
2 year course of MDT  and is associated with age, increasing loads of 
mycobacteria, sub-clinical  cataract  and corneal opacity.
6. Posterior segment lesions    :
        Uveitis in leprosy spares choroids because organisms predilection 
for cooler parts  of the body. Rarely choroidal pearls and retinal pearls 
in  posterior  pole  affecting  vision  has  been  described.   Chorioretinal 
involvement can be in the form of proliferation of RPE, hypopigmented 
patches, peripheral non- specific choroiditis, disseminated choroiditis, 
as well as colloid degeneration in the macula. These are non-specific 
and are the result of reaction to the sensitized uveal tract. 
Ocular complications :
Ocular hypotony :
        Decreased IOP are typically found in patients with  iridocyclitis . 
Chronic uveitis affects secretory  ciliary epithelium  of ciliary body  and 
prevents   its  function  and  hence  hypotony.  Abnormalities   in  the 
autonomic innervation also contributes to ocular  hypotony.
Glaucoma : 
         Glaucoma is often unrecognized and untreated complication of 
leprosy. Secondary open glaucoma with history of chronic uveitis and 
chronic  angle  glaucoma  after   intra  ocular  inflammation  are  most 
prominent types . POAG and acute angle closure glaucoma caused by 
iris bombe also occur.
Cataract  :   
          Primary and secondary cataract formation is responsible for 
nearly  half  of    blindness  in  leprosy.  A  possible  cause  of  cataract 
formation  in leprosy is the reaction of M.leprae with  dopa  produces 
high  local concentration of quinones which are cataractogenic.
           Direct  invasion  of  lens  by  M.leprae  have  never  been 
demonstrated.  Cataract  can  occur  secondary  to  anterior  segment 
damage particularly iridocyclitis. Cataract is the most common cause of 
blindness in leprosy and the social stigmata of the disease often exclude 
patients from receiving surgery.  
     GENETICS 
          The following genes have been associated with leprosy. Hence, 
susceptibility to leprosy may be atleast partially inheritable.
 Susceptible loci on chromosome band 10p 13 and choromosome 6.
 Polymorphisms in the gene promotor regions of TNF                        
( mutibacillary leprosy) and interleukin  (IL-10)
 HLA – HLA-DR2 and HLA –DR3 (tuberculoid disease) as well as 
HLA- DQ1 (lepromatous leprosy) 
 TLR2 mutation in lepromatous leprosy
 Polymorphisms  in  NRAMP1  gene  in  multibacillary  disease  in 
African patients. 
 Genetic  variants  in  the  shared  promotor  region  of  PARK2  and 
PACRG genes. 
 Taq1   polymorphism  (tt  genotype)  at  exon  9  of  the  vitamin  D 
receptor gene.  
     
IMMUNOPATHOLOGY OF LEPROSY
Host response :
      The  varied  and  protracted  manifestations  of  leprosy  arise  from 
immunological  response  of  the host  against  the virtually  non-toxic  M. 
leprae. Glycolipids are the important  surface antigens of mycobacteria . 
Phenolic glycolipid I is unique to mycobacterium leprae. It has immuno 
dominant trisaccharide segment and serves as a valuable chemical marker 
for M.leprae infected tissues. Recent studies suggest HLA DR2 association 
with tuberculoid leprosy.
Humoral immunity   :
     Humoral response in leprosy is not impaired, as patients usually have 
raised  levels  of  serum  immunoglobulin.  Peripheral  blood-  B  cells,  the 
producer  of  antibodies  against  M.leprae  have  been  demonstrated  in 
lepromatous leprosy. They  have been found in the Ig G and Ig M classes. 
The  cell  wall  of  M.Leprae  protects  it  against  these  specific  circulating 
antibodies. Antibodies are harmful when they  react with M.Leprae antigen 
in  the  tissues,  during  type  II  reactions  with  the  deposition  of 
immunoglobulin  and  complement  in  damaged  tissues.  Complement  is 
raised in patients having lepra reaction. Seropositivity proceeds in all types 
of leprosy, particularly in LL patients who have very high antibody levels 
at the time of diagnosis. This is used in the identification of individuals 
progressing towards lepromatous form.
Cell mediated immunity :  
    Cellular  immunity  is  normally  responsible  for  limited  bacterial 
multiplication   and  is  therefore  essential  for  protective  immunity  and 
resistance against leprosy. In tuberculoid leprosy cell mediated immunity 
is  strong and humoral  response  is  weak,  whereas the reverse  is  true in 
lepromatous leprosy.
     In lepromatous leprosy there is profound and specific deficiency of cell 
mediated  immunity  to  M.leprae  which  persists  even  after  prolonged 
chemotherapy.  It  suggests  that  it  may  be  responsible  for  high  risk  of 
relapse in these patients.  M.Leprae is  present  in T- lymphocytes of  LL 
patients. There is insufficient production of IL-2 which results in failure of 
proliferative T-cell lymphocyte response and macrophage activation upon 
exposure to M.leprae.
         Several theories are there for the development of leprosy.   One 
theory  propose  that  leprosy  patients  has  hereditary  cellular 
immunodeficiency  that  cause  them  to  be  unable  to  count  an  effective 
resistance. The other theory suggests  that in early stage,  a few replicatory 
organisms gain access to peripheral  nerves where they are hidden from 
immune  surveillance  system.  Later  as  they  multiply  immune  tolerance 
develops producing a cellular immunodeficiency state.
Aetiological factors to immunological response in leprosy :
      Though, it is accepted that the outcome of M.leprae infection depends 
upon  the  host  immune  response.  The  reason  for  this  diminished  cell 
mediated immunity is not exactly known. Various possibilities suggested 
are :
Genetic constitution:
I. A  possible  association  between  leprosy  and  HLA  haplotype  has 
been suggested by several workers but evidences are not conclusive.
II. Primary fault on T-cells there by rendering them unable to stimulate 
macrophages. 
III. Primary fault in macrophages thus making them unresponsive to    T 
cell stimulation.
IV. Suppressor cell activity – According to this hypothesis , there exists 
a sub population of T-cells (suppressor cells ) which decrease the 
immune response, but several contradictory observations have been 
made by others.
V. Abnormal antigen presentation :
       For a normal and effective cell mediated immunity to occur 
against Mycobacterium leprae-leakage of bacillary antigens  should 
occur to the regional lymph nodes rather than to central lymphoid 
component   (spleen ,  thymus,  bone marrow )  which results in a 
humoral  response and a  suppressed cellular  response .  In leprosy 
there  is  a  continuous  leakage  of  bacilli  into  circulation  from the 
affected nerves as they do not have true lymphatics , thus eliciting a 
stronger humoral than a cellular response. 
Immunopathology of uveitis :
     Uveal  involvement is more common in patients with disease of longer 
duration and in patients on irregular treatment especially those belonging 
to the lepromatous type. Anti-prostaglandin -1 and anti-LAM-B antibodies 
were significantly higher in patients with ongoing uveitis but who were 
skin  smear  negative.  Thus  insufficient  chemotherapy  and  thereby 
incomplete  elimination  of  bacilli  are  the  risk  factors  for  occurrence  of 
uveitis in the quiescent stage of the disease. The role of immunogenetic 
factors in the pathogenesis of uveitis in leprosy has also been extensively 
studied  and  it  has  been  suggested  that  there  is  an  association  between 
HLA-DR2  antigen and susceptibility to uveitis in these patients.
Reactions in leprosy 
The chronic benign course of leprosy at times , interrupted by 
acute  episode  reactions  which  may  cause  irreversible  damage  if  left 
untreated.
History :
      Though Danielsson et  all  and Hansen et all  described a peculiar 
eruption in lepromatous leprosy resembling Erythema nodosum, clinically 
it was Muruta in 1912 who first named the condition Erythema nodosum 
leprosum based on clinical and histopathological features. But ENL was 
not clearly separated from other reactional states of leprosy until 1950’ s 
when Cochrane put forward classification. Real breakthrough was made by 
Ridely  based on his observation on the histology of these lesions.
Classification (Jollife)
1. Type 1- Leprae reaction comprising of upgrading and downgrading 
reactions. 
2. Type 2 – Erythema nodosum leprosum.
Incidence : 
            Though it is difficult to determine the incidence of lepra reaction, 
most authors agree that it’s occurrence has decreased since the advent of 
the sulfones.  A high incidence of about 40%-50% of all forms of lepra 
reactions have been reported. 
Clinical features : 
            Reactional states occur in about one third of patients and are due to 
acute inflammation of the disease. A lepra reaction should be considered as 
a medical emergency requiring immediate care. These states can result in 
permanent  neurological  sequelae  resulting  in  disability  and  deformity. 
Patients at highest risk are those with multibacillary leprosy and / or pre-
existing nerve impairment.
I.  Lepra  reactions  type  I  (reversal)  reactions  usually  affect 
patients  with  borderline  disease.  Reversal  reactions   shift  toward  the 
tuberculoid pole after start of therapy and they are type IV cell mediated 
allergic  hypersensitives.  Puberty,  pregnancy,  child  birth  can  also 
precipitate type I reactions. These reactions usually result in skin erythema, 
with edema and tenderness of peripheral nerves. The peak time for type I 
reaction is during the first 2 months of therapy  up to 12 months.
Type II reaction / ENL :
Occur in 10% of patients with Borderline leprosy and in 20% 
patients  with Lepromatous  leprosy.  These   are  type  III  hypersensitivity 
reactions  with  a  systemic  inflammatory  response  to  immune  complex 
deposition. The most common presenting symptoms are crops of painful 
erythematous  nodules  of the skin  and subcutaneous tissue. Bullae, ulcers, 
necrosis  can  occur.  The  reaction  usually  manifests  after  few  years  of 
therapy.   Although  a  single   acute  episode  is  possible,  relapses  occur 
immediately  or over several years. Associated fever, malaise, iridocylitis, 
dactylitis, orchitis and proteinuria may be present.
        Lucio phenomenon is an unusual type II reaction. It is common in 
Mexico  and  Central  America  and  is  characterized  by  cutaneous 
heamorrhagic infarcts in patients with diffuse lepromatous leprosy. 
Ocular complications during lepra reaction :
    The type I and type II reactions encountered during the course of the 
disease cause ocular involvement within days. Type I lepra reactions 
usually  cause  involvement  of  ophthalmic  division  of  the  trigeminal 
nerve  and  zygomatic  and  temporal  branches  of  the  facial  nerves. 
Lagophthalmos often develops as a result of type I reaction, especially 
when  associated  with  an  erythematous  facial  skin  lesion.  Type  II 
reaction  usually  cause  acute  iridocyclitis  .Type  II  reactions  may 
develop in multibacillary patients with long standing untreated disease, 
but up to 50% patients develop ENL within first year of anti-leprosy 
treatment.  Borderline  lepromatous  and  lepromatous  leprosy  are  in 
particular  risk  of  acute  iridocyclitis  and episcleritis  during treatment 
and  needs yearly follow up.
                             Diagnosis 
A diagnosis of leprosy can be arrived in majority by a proper 
clinical examination alone, which involves a detailed history as well. This 
procedure is called case taking which comprises of 
1) Interrogation :
             -  Bio data of patients 
             - History of contact with other leprosy patients
              - Previous treatment history
              - Presenting compliant
2)Clinical Examination :
              - A thorough inspection of the body for evidence of leprosy
              - Palpation for thickened nerves
3) Laboratory diagnosis :
    Tissue smear testing / slit skin smears:
             An incision is made in the skin and scalpel blade is used to obtain  
fluid from the lesion. The fluid is then placed on the glass slide and stained 
by using Zheil-Neelson acid fast method or Fite method to look for the 
organisms.  The  bacterial  index  is  then  determined  as  the  number  of 
organisms  per  100  bacilli.  Skin  smears  have  high  specificity  but  low 
sensitivity because 70% of all patients with leprosy have negative smears. 
It detects most infectious patients.
4. Skin biopsy :
         Skin biopsy samples are stained with hematoxylin-eosin and Fite-
Faraco.  It is the primary basis for laboratory diagnosis and categorization. 
The  presence  of  an  inflamed  nerve  in  a  skin  biopsy  is  considered  as 
standard criteria for diagnosis. A full thickness skin biopsy sample should 
be taken from an advancing border of an active lesion and should include 
epidermis  and  dermis.  Skin  smears  that  demonstrate  acid  fast  bacilli 
strongly suggest the diagnosis, but the bacilli may not be demonstrable in 
tuberculoid (paucibacillary) form of the disease. The skin biopsy sample 
should be examined for morphological features and presence of acid-fast 
bacilli.  Biopsy is useful  for determining the morphological  index (MPI) 
which  is  used  in  evaluation  and  treatment  of  patients.  The  MI  is  the 
number of viable bacilli per 100 bacilli in leprous tissue.
5) Nerve Biopsy :
             A nerve biopsy can be useful in ruling out diseases such as  
hereditary neuropathies or polyarteritis nodosa. They also help to identify 
abnormalities  in  sub-clinical  leprosy.  It  is   the  only  way  to  diagnose 
definitively in patients with completely neuropathic forms of leprosy.
6) Foot pad culture :
       Mouse  foot  pad  inoculation  is  most  sensitive  in  detecting 
Mycobaterium leprae than slit skin smears. 
It is used for 
1.  Detection of drug resistance
2.  Evaluation of  potency of antileprotic drugs
3.  Detection of viability of bacilli during treatment
The disadvantage of this method is that it is time consuming and 
requires 6-9 months before the results are obtained.
7) Histamine testing :
        This test is used to diagnose post-ganglionic nerve injury. Histamine 
diphosphate is dropped on normal skin and affected skin.  A pinprick is 
made through each site. The site forms a wheal on normal skin but not 
where nerve damage is present.
8) Methacholine sweat testing :
          A intra-dermal injection of methacoline demonstrates the absence of 
sweating in leprous lesions. This testing is useful in dark skinned patients 
in whom the flare with histamine test cannot be seen.
Immunologic tests :
1. Lepromin testing :
   This  test  indicates  host  resistance  to  M.leprae  by  assessing  the 
patients  ability  to  mount  an  granulomatous  response  against  a  skin 
injection of killed M. leprae. It results do not confirm the diagnosis, but 
they  are  useful  in  determining  the  type  of  leprosy.  A  positive  testing 
(>5mm)  indicates  cell-mediated  immunity,  which  is  observed  in 
tuberculoid leprosy.  A negative finding suggests  a lack of  resistance  to 
disease and is observed in lepromatous leprosy. A negative test result also 
indicates a poor prognosis.
Procedure:
      To perform this test, bacillary suspension is injected into forearm. An 
assessment of the reaction at 48 hours is called  Fernandez reaction and 
indicates  delayed  hypersensitivity  to  antigens  of  M.leprae  or 
Mycobacterium that cross react with M.leprae.  When the reaction is read 
at  3-4 weeks  it  is  called  Mitsuda reaction and indicates   that  immune 
system is capable of mounting an efficient cell-mediated response.
2.PGL -1 :
    This is a specific serological test. It is based on antibodies to phenolic 
glycolipid-1  –  (PGL-1).  This  test  has  a  sensitivity  of  95  %   for  the 
detection of lepromatous disease, but only 30% for tuberculoid disease.
3. Lymphocyte Migration Inhibition test (LMIT)   :  
     As  determined  by  a  lymphocyte  transformation  and  LMIT,  cell-
mediated  immunity  is  absent  in  lepromatous  form  of  the  disease  but 
present in tuberculoid form of the disease.
Serology and polymerase chain reaction :
Although  these  tests  are  useful  in  detecting  multibacillary 
disease, they are not widely used because they fail to detect early or milder 
forms of the disease reliably.
 Serology can be used to detect antibodies to M.leprae specific 
PGL-1. This test is useful primarily in patients with untreated LL, as 90% 
of patients have antibodies. However antibodies are present only in 40-
50% patients with paucibacillary disease.
PCR analysis can be used to detect and identify M.leprae. The 
technique  is  used  most  often  when  acid  fast  bacilli  are  detected  but 
clinical/ histopathological features are atypical. It is not useful when AFB 
is not detected by light microscopy. M.leprae DNA can be detected by 
using  RT-PCR  in  ocular  tissues,when  acid  fast  bacilli  are  seen  in 
histopathological  section  and  when  the  diagnosis  of   leprosy  is 
inconclusive.   RT-PCR  for  M.leprae  DNA  could  be  used  as  a  rapid 
confirmatory test to identify the presence of M.leprae and therefore the 
diagnosis of leprosy. The development of one –step reverse transcriptase 
PCR (RT-PCR) may be most sensitive in detecting bacilli in slit smears 
and skin  biopsy  specimens.  This  RNA based assay  is  also  effective  in 
monitoring bacteria clearance during therapy.
Imaging studies :
Radiographs :
       Plain radiographs are useful to detect and monitor leprosy induced 
bone  changes.  Resorption,  fragmentation  and  mal-aligned  fractures  are 
common signs of leprosy induced bone changes.  Medullary sclerosis or 
wavy diaphyseal borders indicate diaphyseal whittling.
Histologic findings :
In  TT  form  well  developed  epitheloid  granulomas  are 
observed in the papillary dermis, often around neovascular structures. The 
granulomas are surrounded by lymphocytes which extend into epidermis. 
Langerhans giant cells are common. Dermal nerves are destroyed / swollen 
because of  the granulomas.  Acid fast  bacilli  are not observed. S-100 is 
useful in identifying nerve fragmentation and differentiating it . 
     In the LL form, a diffuse infiltrate of  foamy macrophages is 
present  in the dermis  below the sub-epidermal grenz zone. An enormous 
number of AFB develop within foamy macrophages, singly or in clumps 
called globi. Lymphocytes are scant and giant cells are typically absent. 
Numerous bacilli invade the nerves but these are fairly well preserved with 
little infiltrate. Nodular / dermatofibroma-like lesions in LL, referred to as 
histoid leprosy  result  in  fascicular  arrangement  of  spindle  cells  in  the 
dermis admixed with foamy macrophages that contain numerous bacilli.
             Histopathology of ocular tissues discloses far more silent chronic  
iridocyclitis  in  leprosy  patients  than are  diagnosed  clinically.  AFB can 
persist  in the iris tissue even after completion of MDT. Smooth muscle 
disruption and destruction  causes miotic pupil in leprosy and has been 
conclusively demonstrated histopathologically.
MANAGEMENT
                The  management  of  leprosy  includes  pharmacothreapy  and 
physical,  social,  psychological  rehabilitation.  The  goals  of 
pharmacotherapy  are  to  stop  the  infection,  reduce  morbidity,  prevent 
complications  and  eradicate  the  disease.  Since  1981  MDT  has  been 
advocated by World Health Organisation (WHO) and US. 
          MDT prevents dapsone resistance, reduces relapses, reactions 
and disabilities. The length of treatment ranges from 6 months to 2years. 
Patients  are  considered  non-infectious  within  1-2  weeks  of  treatment 
(usually after first dose )
Current WHO recommendations for treatment of leprosy are as follows :
Paucibacillary disease  :   
          Dapsone 100mg/day plus rifampicin 600mg once a month for 6 
months .
Multibacillary disease : 
          Dapsone 100mg/day plus rifampicin 600mg once a month plus 
clofazimine 300mg once a month and 50 mg /day for 1year.
MDT Regimens :
Treatment for lepra Reaction :






Up  to  1mg/kg/day  then 
gradually reduced
Up to  1mg/kg/day then 
gradually reduced     
Upto 300mg Upto 400mg
Combination therapy is recommended in ENL
Thalidomide should be avoided in women of child bearing age
 
-    Corticosteroid treatment  is aimed at  controlling acute inflammation, 
relieving  pain  and  reverses  nerve  and  eye  damage.   With  treatment, 
approximately 60-70% of patients nerve function is recovered. If neuritis is 
absent, non-steroidal anti-inflammatory drugs may be useful. 
Erythema nodosum leprosum :
        The use of clofazamine in MDT substantially reduces the incidence of 
ENL to 5% clofazamine has also been used to treat ENL.
         Thalidomide is effective in ENL except in case of neuritis / Iritis in  
which  case,  corticosteroids  should  be  used.   Other  treatment  therapies 
reported to be effective include colchicine, pentoxiphylline, cyclosporine 
A, intravenous immunoglobulin (IVIG) and infliximab. Lowering the dose 
of dapsone may decrease the severity of bullae and ulcers
         In lucio phenomenon, thalidomide is ineffective. Azathioprine / 
Cyclophosphamide  with  corticosteroids  with  or  without  plasmapheresis 
has been used.
Prevention and treatment of Deformites :
      Potential deformities can be prevented by educating patients about how 
to minimize  existing nerve damage and by treating any sequlae of  this 
damage. Close follow up is important to ensure patient compliance.
     Emergency  surgery  may  be  necessary  if  a  patient  with  profound 
inflammation  presents  with  nerve  abscess  /  loss  of  nerve  function 
secondary to compression.Prompt recognition and surgical drainage of the 
abscess can often restore nerve function.
      Reconstructive  surgery  can  be  used  to  repair  nasal  collapse   in 
LL.Other  surgery  may  be  needed to  improve  function  or  for  cosmesis, 
Contractures can be surgically repaired .
Management of ocular complications of leprosy :  
Madarosis Island of neurovascular pedicle graft from the scalp
Upper lid ectropion Blepharoplasty with correction of lid inversion 
Lower lid ectropion Tarsal strip procedure
Trichiasis Cryoablation of abnormal lashes
Dacryocystitis 
Dacryoadenitis
Systemic  antibiotics  with  dacryorhinostomy  / 
dacryocystectomy.
Systemic antibiotics with anti-inflammatory drugs
Lagophthalmos  with 
exposure
Acute  :  Immediate  treatment  with  prednisolone, 
thalidomide or clofazamine.
Chronic  :  Eyelid  exercise  using  maximum  effort  with 
artificial lubricants .
Tarsorraphy / temporalis muscle transfer.  
Limbal lepromas Systemic antileprotic  therapy
Episcleritis  and 
scleritis
Topical / systemic anti-inflammatory agents
Corneal hypesthesia Patient education about regular surveillance
Eye protection with sun glasses & lubricants
Acute iridocyclitis 
                           Chr
onic iridocyclitis
Treatment of systemic ENL if present
Topical steroids & mydriatics / cycloplegic agents , IOP 
monitoring Topical mydriatics
Topical steroids if anterior chamber reaction is severe
Cataract Cataract extraction with or without implantation of IOL 
depending on the presence or absence of uveitis
Glaucoma Standard  management  of  open  angle  glaucoma  ,angle 
closure or complicated glaucoma with synechiae
Drug and side effects :
Rifampicin (RFP) :
   The drug is administered in a single monthly dose, a protocol 
for  which  no  significant  toxic  effect  has  been  reported.  Exceptionally 
bactericidal against M.leprae and single dose of 600mg of RFP is capable 
of killing 99.9% or more of viable organisms. However the rate of killing 
is not proportionately enhanced by subsequent doses. It has been suggested 
that  RFP may exert  a  delayed antibiotic  effect  for  several  days  during 
which organisms multiplication is inhibited. The high bactericidal activity 
of RFP made feasible the application of the single monthly dose, which is 
cost-effective for leprosy control programs.
Side effects :
    Red colouration of  urine and other  side effects  include skin rash , 
peripheral neuropathy, hemolytic anemia, flu-like syndrome.
Di-amino diphenyl sulfonoe (DDS, dapsone ) :
        Until widespread resistant strains to drug were reported,  dapsone 
which is bacteriostatic / weakly bactericidal against M.leprae was for years 
the  mainstay  treatment  regimen  for  leprosy.  Subsequently  its  use  in 
combination with other drugs has become essential to slow or prevent the 
development of resistance. The drug has demonstrated an acceptable level 
of safety in the dosage used in MDT.
Side effects :
          Besides occasional cutaneous eruptions, side effects that necessitate 
discontinuation are rare. Patients known to be allergic to any of sulfa drugs 
should  be  spared  dapsone.  Anemia,  hemolytic  and  methemoglobinemia 
may develop but are more significant in patients deficient for glucose-6-
phosphodihydrogenase (G6PD)
Clofazimine (CLF) : 
           CLF which preferentially binds to mycobacterial DNA inhibits both 
mycobacterial  growth and exerts a slow bactericidal effect  on M.leprae. 
Because of its anti-inflammatory properties it is suggested for the erythema 
nodosum leprosum reactions by mechanisms still poorly understood. 
    Most active when administered daily , dosage used for MDT is well 
tolerated  and  has  not  shown  significant  toxicity.  Because  CLF  is  a 
repository  drug,  stored  in  the  body  after  administration  and  slowly 
excreted. It is given as a loading dose of 300mg once a month to ensure 
that the optimal amount of CLF is maintained in the body tissue even if 
patients occasionally miss the daily dose.
Side effects :
       Brownish black discolouration  and dryness of skin. These usually 
disappear within few months of treatment suspension. Other side effects 
include abdominal pain, diarrhea, phototoxicity.
Ofloxacin (oflx):
      OFLX a synthetic  fluoroquinolone  acts  as  a  specific  inhibitor  of 
bacterial  DNA  gyrase  and  has  shown  efficiency  in  the  treatment  of 
M.leprae.  Chromosomal  resistance  of  negligible  clinical  relevance   has 
been reported .
Minocycline (MINO) :
       MINO is a semisynthetic tetracycline in susceptible organisms and 
induces bateriostasis by inhibiting protein synthesis.
        However from the curative and cost-effectiveness points of view ,the 
WHO recommended MDT remains  to date the best combination regimen 
of  the worldwide leprosy control programme.
Laboratory monitoring for drugs used to treat leprosy includes : 
Drug Laboratory studies Frequency






      CBC, platelets
      G6PD,CBC
CBC,platelets,hemoglobulin




     Every 6 months




The basic factors in the prevention of leprosy in endemic regions are:
1. Case  finding  and  prompt  treatment  of  all  cases  found,  with 
multidrug therapy.
2. Keeping close contacts of patients under surveillance.
3. Vaccination of all young children, especially those born in leprous 
families and to lepromin negative contacts of index cases with BCG 
vaccine.
4. Improvement in socioeconomic condition.
5. Health  education  and  publicity  about  leprosy  and  about  early 
presentation for diagnosis and cure by multidrug therapy
Attempts  to  develop  a  vaccine  against  M.leprae  are  being 
made that may induce immunity in non-infectious patients and a high 
level of immunity in leprosy patients. This is based on the theory that 
cross immunity exists between TB and leprosy. Thus BCG is a cheap 
and safe substitute until a specific anti-leprosy vaccine is discovered. 
But  the  extent  to  which  elimination  and  eradication  of  leprosy  will 
depend mainly on improvement in socioeconomic conditions as Latapi 
the renowned Mexican Leprologist said` Leprosy cannot be completely 
rooted out with physicians, control officers, leprosaria and propaganda’. 
It  will  disappear  when  the  economic  and  cultural  factors  change, 
because leprosy is the thermometer of civilization.
The strategy for leprosy elimination :
         The following actions are part of the ongoing leprosy elimination 
campaign :
1) Ensuring  accessible  and  uninterrupted  MDT  services  are 
available to all patients through flexible and patient friendly drug 
delivery systems.
2) Ensuring  the  sustainability  of  MDT  services  by  integrating 
leprosy services into general health services. Building the ability 
of general health workers to treat leprosy.
3) Encouraging  self  reporting  and  early  treatment  by  promoting 
community awareness and changing the image of leprosy.
4) Monitoring  the  performance  of  MDT  services  the  quality  of 
patients care and the progress being made towards elimination 
through national disease surveillance systems.  
AIMS  AND OBJECTIVES
1.   To analyse the ocular manifestations of leprosy in a  
       hospital population.
2.   To analyse the incidence of ocular complications and 
      visual outcome.
MATERIALS AND METHODS
          A prospective and descriptive study on ocular manifestations of 
leprosy and its management was conducted in Government Rajaji  Hospital 
– Department of ophthalmology, Madurai. This study was conducted from 
January  2007  to  Dec-2007,  during  which  46  patients  with  ocular 
manifestations were analyzed.   In this study all the patients with systemic 
leprosy who presented to the department of Dermatology outpatient were 
referred  to  the  department  of  Ophthalmology  and  screened  for  ocular 
manifestations. 
Inclusion criteria :
     All leprosy patients who attended department of ophthalmology, GRH 
in the period from Jan-2007   to Dec -2007.
Exclusion criteria :  
    Patients with co-morbid condition like HIV were excluded from the 
study.
Clinical evaluation : 
         In  all  these  patients  demographic  data  like age,  sex,  place  of 
residence  were  documented.  A  detailed  history  regarding  systemic 
symptoms of leprosy like defective vision, redness, pain, loss of eyelids 
were documented.
         An elaborate treatment history regarding 
(i)      Year of onset of skin lesions and the latency period if any, 
of  the start of systemic treatment.
(ii)       Duration and regularity of treatment.
(iii) Type of treatment – monodrug / multidrug were elicited.
           The patients were examined for ocular manifestations and systemic 
manifestations of leprosy.
 Ocular examination included :
(i) Best corrected visual acuity.
(ii) Slit lamp examination for the type of keratic precipitates, anterior 
chamber  reactions,  iris  features,  posterior  synechiae,  lens 
changes and scleritis.
(iii) Dilated fundus examination by indirect ophthalmoscopy, +90D 
slitlamp biomicroscopy.
(iv) SLE  :  To  look  for  episcleritis,  scleritis,  keratitis,  exposure 
keratopathy, uveitis and cataract.
(v) Corneal sensation : Tested by asking the patient to look up and 
applying tail end of wisp of cotton on the cornea 2mm from the 
limbus at the 6’ clock position and categorizing the sensation as 
normal  if  the  patient  responded  by  retracting  the  head  (or) 
closing the eyelids. It is impaired if the patient didn’t.
(vi) Detailed external ocular examination done with the help of torch 
light to look for madarosis, lagophthalmos, lid nodules.




Based on this patients were grouped according to WHO classification 
of visual impairment and blindness.
Grading Category of 
visual 
Impairment
Best corrected visual acuity in the better eye
0 Normal 6/6 to 6/18 i.e – can see 6/18 or better
1 Visual 
Impairment
<6/18 to 6/60 i.e – cannot see 6/18 can see 6/60
2 Severe  Visual 
Impairment
<6/60 to 3/60 i.e – cannot see 6/60 can see 3/60
3 Blind <3/60 to 1/60 i.e – cannot see 3/60 can see 1/60
4 Blind <1/60 to only light perception i.e –cannot see 1/60 
can see light
5 Blind No light perception i.e – cannot see light
6 Undetermined or 
unspecified
       Intra ocular pressure was recorded in all patients above 40 years by 
schiotz  tonometer.  Gonioscopy  was  done  with  Goldmann  goniolens  in 
suspected  cases  of  narrow  angles  and  graded  according  to  shaffers 
classification. Fields were done in  Humphery perimeter in selected cases.
     After  establishing the diagnosis,  appropriate treatment  was started. 
Patients  with acute granulomatous or non- granulomatous  uveitis were 
treated with topical steroids – 1% prednisolone acetate frequency being 
determined by severity of iritis at the time of presentation, cycloplegics – 
homatropine  eyedrops  2  times/day  and   oral  non-steroidal  anti-
inflammatory agents – tablet Ibubrofen 500 mg twice a day. Patients with 
episcleritis  and  scleritis  were  treated  with  topical  steroids  like  % 
prednisolone  acetate.   Patients  with  severe  or  recurrent  intra-  ocular 
inflammation suspected to be due to active leprosy were started on anti-
leprosy treatment and systemic steroids after consulting the dermatologists. 
Anti-  glaucoma  medications  were  started  in  patients  with  raised  intra-
ocular pressure. Secondary angle closure glaucoma patients with cataract 
underwent  cataract  extraction   with  intraocular  lens  implantation   after 
ocular inflammation is controlled with topical steroids or systemic steroids. 
Lateral tarsorraphy was done in patients with lagophthalmos with exposure 
keratopathy. Patients were followed over subsequent visits.  During each 
visit BCVA, ocular status  and skin lesion were assessed.
    At the end of the study period, all the data were analyzed. The pattern of 
ocular  involvement  in  these  patients  were  analyzed.  The  correlation 
between  anti-leprosy treatment and  ocular involvement were analyzed. 
The visual outcome of the treatment were analyzed for those patients who 
had atleast three follow up’s during the study period. 
PROFORMA
Name : Age : Date  :
Sex :     1:  Male,  2 : Female Occupation :
Address :
History  (Present – 1,  Absent – 2)
Skin Lesion Weakness or anaesthesia of limbs
Nasal symptoms Edema of legs
    Year of onset of  skin lesion ____ year of diagnosis      year of treatment
Type of Leprosy
    1 – TT 2 – BT 3 – BB 4 -  BL 5 -  LL           
Ocular symptoms of Leprosy 
1. Pain 2.  Redness  3.  DV   4. Loss of eyebrows  5. Inability to close lids
Occurrence of ocular symptoms
1. During treatment 2.  After treatment
Lepra Reaction  
1 – Present ,   2 – Absent
Type – 1 Erythema of existing lesions Nerve palsy
Edema of existing lesion
Type – II Fever Epistaxis Edema of legs
Epididymoorchitis Malaise Joint pain
New skin lesions Dactylitis Others
Precipitating factor
1.   Pregnancy    2.  Vaccination     3.  Trauma   4. Recent ALT  5. Nil
Ocular symptoms of Lepra reaction
A)    1.  Pain    2.  Redness   3. Photophobia   4.  DV   5.  Floaters
B)    No.of episodes of Lepra reaction
C)    Time of occurrence
           1.  Before treatment   2.  During   3.  After treatment
Treatment given for ocular symptoms of lepra reaction
1. Topical steroids    2.  Systemic steroids 3. ALT    4. Antiglacoma 
drug
5.  NSAID    6.  Thalidomide 7. Others
Dosage    :   ____________
Duration  :  _____________
Treatment History for leprosy
1. Multidrug     2.  Monodrug    3.  Mono to multi drug   4. Details not 
known
5. Treatment not taken   
A)  Drugs :   Dapsone     Rifampicin   Clofazamine    Steroids   Others
Dosage    :   ____________
Duration  :  _____________
B)  Total duration of treatment
C)  Treatment Status  :    1. Completed treatment   2.  Undergoing 
treatment
D)  Compliance          :       1.   Regular                      2.  Irregular
EXAMINATION :  Systemic :
Skin   :  Hypopigmented patches    1.   0     2.  < 6    3.  >  6  
Neuropathy  :  1. Trigeminal   2.  Facial  3.  Ulnar  4. Radial  5. Median 
   6. Greater auricular   7. Deep peroneal  8. Posterior tibial  
  9. No neuropathy
1.  Right 2.  Left 3.  Both
Deformities of Extremities    Nasal deformities      Present – 1,  Absent  - 2
Ocular Examination :
Laterality : 1. Unilateral 2.  Bilateral     3. One eyed




















1.  Unilateral 2. Bilateral 3. Not done   4. combined 
surgery
Type of surgery : ____________________  1.  R E     2.  L E
Post op. Complications :
1.   Present 2.  Absent
Post of vision :  ____________________________
Follow up I II III IV V
A BCVA  (RE)
BCVA  (LE)
B Skin lesions
C Ocular lesions (RE)
                        (LE)




      In this study, 46 patients with ocular leprosy were analysed.  Among 
46 patients, 4 had lepra reaction.  Patients demographic characteristics are 
shown in table 1 and 2. Most of the patients were in 6th – 7th decade of life. 
Majority of patients (80.43%) were males.
         Type of leprosy is shown in table 3.  Majority of patients (80.43%) 
had  lepromatous  leprosy.   Among  lepromatous  leprosy,  lepra  reactions 
were noted in 4 patients.  The time of occurrence of ocular manifestations 
in leprosy is shown in table 4.  Ocular manifestations were predominantly 
seen (91.3%) after treatment.
        The details of anti-leprosy treatment are shown in table 5and 6. 
Among 46 patients 44 of them had already taken treatment (94.4%).  In the 
remaining 2 patients type of treatment was not known in 1 patient and 1 
patient didn’t receive treatment. The predominant regimen were multidrug 
therapy (54.34%) and monotherapy (33.3%). 
       67.39% of patients had successfully  completed their treatment with 
good compliance.  Systemic features  such as skin lesions, neuropathy are 
shown in the table 8 and 9  respectively.  Among them only 17.39% had 
skin  lesions,  the  remaining  82.61%  had  no  skin lesions.   Peripheral 
neuropathy was observed in 31.8% of patients.  Ulnar nerve was the most 
common  neuropathy  followed  by  common  peroneal  nerve  and  greater 
auricular  nerve in  both the  subgroup of patients.   Data   obtained from 
(ocular evaluation) are discussed below.  Table 10 shows that majority 
(72.72%) of patients had bilateral involvement. 12 patients had unilateral 
involvement  and  6  were  monocular.  Table  11  shows  that  madarosis 
(80.30%) was the most common adenexal ocular manifestation in both the 
sub groups.
   Table 12 and 13 shows the pattern of   ocular involvement  in these 
patients.  Chronic  granulomatous  uveitis  was  seen  in  36.52%  of  eyes. 
Decreased corneal sensation was observed in 37.1 % of patients .  Corneal 
leucoma was observed in (6.12% ) and corneal  ulcer   was observed in 
(2.04%)  of  patients  .   Episcleritis  (4.54%)  and  scleritis  (4.54%)  were 
reported. 45 eyes out of 66 eyes showed iris atrophy and iris nodules were 
observed in 1 patient. Lepra pearls were seen in 1 patient.
        Table 14 shows the analysis of type of cataract. 30 eyes had cataract 
of which 17 were complicated cataract, 13 were senile type. Findings of 
posterior segment are showed majority of patients (84.84%) had normal 
fundus. Glaucomatous disc was observed in 3.03% patients. Fundus view 
was hazy and could not be assessed due to cataract in 10.68% patients.
   Intraocular pressure was recorded in all patients. Majority had normal 
IOP. Ocular hypotony was seen in 6.06% of patients. Glaucoma was seen 
in 3.03% of patients. Antiglaucoma medications were  required in 11.11% 
of patients.  
The details of  cataract surgeries   were shown in table.  20 
out  of  66  eyes  underwent  cataract  surgery.  One  patient  underwent 
combined procedure (cataract  surgery with trabeculectomy).    95% had 
good visual outcome.  
         WHO grading of visual impairment of the patients were shown in 
table. 10.86% had severe visual impairment.  10.88% of patients met with 
blindness criteria. 
        Potentially sight threatening lesions (PSTL) are those that cause 
visual  impairment  and  blindness.  PSTL  include  lagopthalmos,  corneal 
hyposensitivity,  keratitis,  iris  involvement  and  post  operative 
inflammation.
     Lagophthalmos  (4  patients)  were  examined  for  adequate  Bells 
phenomenon  and  corneal  sensation.   Patients  with  lagophthalmos  with 
indadequate  Bells  phenomenon  were  treated  with  temporary  lateral 
tarsorraphy  (8  patients).   They  were  observed  for  exposure  keratitis, 
secondary bacterial keratitis during their follow up.
       Patients having neurotrophic and neuroparalytic keratitis (7patients) 
were observed for exposure keratitis and secondary bacterial keratitis. Two 
patients  were not  compliant  with their  follow up and developed severe 
secondary bacterial keratitis and perforation.  Our best treatment prevented 
them developing blindness and gained vision 4/60.  
      Cataract surgery in inflamed eyes is a challenge to even an experienced 
ophthalmic  surgeon.   Preoperatively  all  patients  were  evaluated  in  Slit 
lamp to rule out  active inflammation.   All  patients  were preoperatively 
treated with hourly steroid eye drops. 
       Due to our meticulous surgery and minimum tissue handling during 
surgery  we landed  up with  few post  operative  complications.   Patients 
were  given  intense  steroid  therapy  depending  upon  the  severity  of 
inflammation. Inspite of our best efforts, 2 patients developed severe post 
op inflammation leading to deterioration of vision upto 6/60.
 Remaining  52.17  %  patients  had  normal  visual  acuity. 
Majority of patients (66.67%) of patients were treated with steroids. Anti-
leprosy treatment was restarted in 19.44% of patients.  One patient with 
history of lepra reaction were treated with thalidomide. 
The  follow up and treatment response of these patients are 
analysed.    19  patients  had  come  for  more  than  3  follow ups.  Ocular 
inflammation  had  improved  in  75% patients,  static  in  8.33%.  In  these 
patients  with  history  of  lepra  reaction  only  one  patient  had  come  for 
regular follow up and there was good improvement in ocular condition. 
The skin lesion was static in all patients.   
  
Table   -1 Age distribution
Age group No.of leprosy patients 
30  -  39 2
40  -  49 7
50  - 59 18
60  - 69 16
70  - 79 3
Total 46
        Most common age group 6th – 7th decade
Table  - 2   Gender
Gender No .of leprosy patients Percentage
Male 37 80.5 
Female 9 19.5
Total 46 100
Table – 3       Type of leprosy




Table  -4 time of occurrence of ocular symptoms of leprosy
Time of  occurrence of 
ocular symptoms
No.of leprosy patients Percentage
During treatment 4 8.7
After treatment 42 91.3
Total 46 100
Table – 5  Time of occurrence of lepra reaction
Treatment  status No .of patients with 
lepra reaction
Before start of treatment 0
While on treatment 3
After completing treatment 1
Total 4
Table -  6   Treatment History
Type of medical treatment No .of leprosy patients
Multidrug 25
Monodrug 13
Monodrug to Multidrug 6
Details not known 1
Treatment not taken 1
Total 46
Table   - 7  Compliance
Compliance No.of leprosy patients
Regular 30
Irregular 14
Treatment details not known 2
Total 46
Table - 8  Skin lesions





Table  -9 Neuropathy










Table -10   -   Laterality





Table   - 11 Ocular Adenexal manifestations





Table  -12   Ocular manifestations
Clinical signs No .of eyes
Episcleritis 3
Scleritis 3
Decreased corneal sensation 24
Acute granulomatous uveitis 16
Chronic granulomatous uveitis 24
Acute nongranulomatous uveitis 6
Chronic nongranulomatous uveitis 4
Adherent leucoma 4
Corneal ulcer 2
Table  -13     Cataract
Type of cataract No. of eyes Percentage
Complicated cataract 17 25.5
Senile cataract 13 20
Nil 36 54.5
Total 66 100
Table -14   Grading  of visual impairment
Grade No .of eyes Percentage
Normal 24 52
Visual impairment 12 26
Severe visual impairment 5 11
Blind 5 11
Total 46 100
Table -15 Immediate postoperative vision after cataract surgery
Best corrected visual acuity No .of eyes
6/6       -        6/12 17
6/18     -        6/36 2
 <  6/60 1
Total 20
Table -16     Follow up
Number of follow up No .of leprosy patients
Nil 15
1  -  2 12
3  -  5 19
Total 46
Table -17   Treatment response for inflammation
Treatment response of 
inflammation







Leprosy is a disease which is still  endemic in 120 developing 
countries and also contributes to significant cause of blindness. Most of the 
blindness is avoidable and could have been prevented by early diagnosis of 
ocular leprosy, early systemic anti-leprosy treatment, timely treatment of 
immune reactions and prompt treatment of ocular complications. Our study 
results were consistent with this finding.
    According to longitudinal study on ocular leprosy (Ethiopia, India 
&  Philippines)  2.8%  are  blind  at  the  time  of  diagnosis  and  11%  had 
potentially blinding complications. Our study results were consistent with 
this findings.  
 The demographic profile of these 46 patients in this current study 
is consistent with published reports.  The age group of presentation in our 
study was between 4th -8th decade majority being in their 6th -7th decade. 
This is similar to previous reports.  The sex incidence in our study revealed 
a  male:female  ratio  (  4:1)  which  is  comparable  to  other  studies  in 
literature.  The  male  preponderance  is  because  males  in  general  expose 
themselves to greater risks of infection as a result of their life style. This 
male  preponderance  is  seen  even  in  patients  with  a  history  of  lepra 
reaction, on the other hand women may not tend to seek medical help even 
when it is required.
        It is well known that persistence or recurrence of inflammation 
can occur  long after  systemic  infection  was treated  with ALT.  Though 
routine  skin  smear  may  be  negative  after  completion  of  treatment,  the 
persistence  of  M.leprae  in  the  fibrosed  nerves  may  be  responsible  for 
chronic  uveitis  seen  in  these  patients.  Espirito  et  al  had  reported  an 
incidence ranging from 5.3% to 63% of chronic iridocyclitis in patients 
treated for leprosy.
   Systemic evaluation revealed that  majority had no skin lesions at 
the  time  of  presentation  of  ocular  symptoms.  The  most  common 
neuropathy was ulnar nerve followed by deep peroneal nerve in both the 
subgroup of patients. Deformities of the extremities and depressed nasal 
bridge were found to be more common in lepromatous type.
   In  ocular  evaluation  madarosis  was  the  most  common  ocular 
adenexal  manifestation  seen in our  study. These  findings  are consistent 
with previous reports.  Lagophthalmos  was seen in 33.3% patients.   In 
patients with Lagophthalmos the Bells phenomenon was assessed.  Patient 
with adequate Bells phenomenon (4 patients) were treated with lubricants. 
Patients with inadequate Bells phenomenon were treated with temporary 
lateral tarsorraphy (8patients). The reports of other abnormalities of lid 
like entropion and ectropion  were very few. Among 46 patients 5 patients 
had phthsis bulbi at presentation, the reason for phthisis was not evaluated.
  The commonest form of uveitis in  lepromatous leprosy is chronic 
low grade insidious type of uveitis. In our study  the commonest type of 
uveitis is chronic low grade uveitis which is also consistent with this fact.
      Iris atophy is a common finding in the chronic uveitis.  Iris pearls 
are  chalky  white  particles  in  the  superficial  connective  tissue  of  the 
pupillary margin Mithal et al had reported an incidence of these findings 
which are compared with our study.  Iris atrophy was seen in 60 %.  
     Episcleritis and scleritis were seen in 4.54% of patients. None of 
the  patients  with  history  of  lepra  reaction  had  scleritis  or  episcleritis. 
Tajamul khan et al in his study found the incidence of episcleritis to be 
around 1%.
    Leprotic pearl were seen 1 patient and iris nodules were seen in 1 
patient. According to a study Ebenezor et al it was found that iris atrophy 
continues to develop in 3% of patients with MB leprosy every year after 
they complete  their  2  year  course  of  MDT and is  associated  with age, 
increasing loads of mycobacteria,  subclinical  inflammation,  cataract and 
corneal opacity.
CONCLUSION
  In this prospective and descriptive study done in Government 
Rajaji Hospital during January 2007 to December 2007, 46 patients 
with ocular leprosy were analysed.
    Among these 46 patients who presented with ocular leprosy, 4 
patients had history of lepra reaction. 
  Cataract  surgery  alone  was  done  in  19  patients.  Combined 
surgery  was  done  in  1  patient.   95% of  patients  had  good  visual 
outcome after cataract surgery.
Temporary  lateral  tarsorraphy  was  done  in  8  patients  of 
lagophthalmos having inadequate Bells phenomenon.
   Majority of these patients had developed ocular manifestations 
despite completing anti-leprosy treatment with good compliance, thus 
emphasizing  the  importance  of  monitoring  patients  even  after 
completing treatment.
     Majority of patients treated for ocular inflammation  had good 
visual outcome. 
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